药品注册申请号:020080
申请类型:NDA (新药申请)
申请人:GLAXOSMITHKLINE
申请人全名:GLAXOSMITHKLINE
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 IMITREX SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No AP 1992/12/28 1992/12/28 Discontinued
002 IMITREX STATDOSE SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) Yes Yes AB 2006/02/01 Prescription
003 IMITREX STATDOSE SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Yes Yes AB 1996/12/23 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2021/12/20 SUPPL-54(补充) Approval Labeling STANDARD
2021/03/23 SUPPL-53(补充) Approval Labeling STANDARD
2018/07/17 SUPPL-52(补充) Approval Labeling STANDARD
2017/12/14 SUPPL-50(补充) Approval Labeling STANDARD
2015/11/19 SUPPL-49(补充) Approval Labeling STANDARD
2015/06/11 SUPPL-48(补充) Approval Labeling STANDARD
2012/10/02 SUPPL-45(补充) Approval Labeling UNKNOWN
2012/10/02 SUPPL-41(补充) Approval Labeling STANDARD
2012/10/02 SUPPL-40(补充) Approval Labeling STANDARD
2012/10/02 SUPPL-39(补充) Approval Labeling STANDARD
2010/07/21 SUPPL-38(补充) Approval Labeling STANDARD
2006/02/01 SUPPL-36(补充) Approval Efficacy UNKNOWN
2003/07/28 SUPPL-30(补充) Approval Labeling STANDARD
2003/01/03 SUPPL-29(补充) Approval Labeling STANDARD
2001/02/02 SUPPL-27(补充) Approval Labeling STANDARD
2001/02/02 SUPPL-26(补充) Approval Labeling STANDARD
2001/02/02 SUPPL-25(补充) Approval Labeling STANDARD
2001/02/02 SUPPL-24(补充) Approval Labeling STANDARD
2001/02/02 SUPPL-21(补充) Approval Labeling STANDARD
1997/12/16 SUPPL-22(补充) Approval Manufacturing (CMC) PRIORITY
1997/11/26 SUPPL-23(补充) Approval Manufacturing (CMC) PRIORITY
1996/12/23 SUPPL-5(补充) Approval Manufacturing (CMC) PRIORITY
1996/05/22 SUPPL-4(补充) Approval Efficacy UNKNOWN
1996/03/28 SUPPL-20(补充) Approval Manufacturing (CMC) PRIORITY
1995/11/29 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
1995/10/05 SUPPL-17(补充) Approval Manufacturing (CMC) PRIORITY
1995/06/07 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1994/08/17 SUPPL-3(补充) Approval Labeling STANDARD
1993/09/30 SUPPL-2(补充) Approval Manufacturing (CMC) PRIORITY
1992/12/28 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 4816470 2006/12/28 U-72 PDF格式**本条是由Drugfuture回溯的历史信息**
4816470*PED 2007/06/28 PDF格式**本条是由Drugfuture回溯的历史信息**
5037845 2008/08/06 U-72 PDF格式**本条是由Drugfuture回溯的历史信息**
5037845*PED 2009/02/06 PDF格式**本条是由Drugfuture回溯的历史信息**
002 5037845 2008/08/06 Y Y U-848 PDF格式**本条是由Drugfuture回溯的历史信息**
5037845*PED 2009/02/06 PDF格式**本条是由Drugfuture回溯的历史信息**
003 4816470 2006/12/28 U-72 PDF格式**本条是由Drugfuture回溯的历史信息**
4816470*PED 2007/06/28 PDF格式**本条是由Drugfuture回溯的历史信息**
5037845 2008/08/06 U-72 PDF格式**本条是由Drugfuture回溯的历史信息**
5037845*PED 2009/02/06 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:SUMATRIPTAN SUCCINATE 剂型/给药途径:INJECTABLE;SUBCUTANEOUS 规格:EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
020080 001 NDA IMITREX SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Discontinued Yes No AP 1992/12/28 GLAXOSMITHKLINE
活性成分:SUMATRIPTAN SUCCINATE 剂型/给药途径:INJECTABLE;SUBCUTANEOUS 规格:EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
020080 002 NDA IMITREX STATDOSE SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) Prescription Yes Yes AB 2006/02/01 GLAXOSMITHKLINE
078319 001 ANDA SUMATRIPTAN SUCCINATE SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) Discontinued No No AB 2015/12/10 ANTARES PHARMA INC
活性成分:SUMATRIPTAN SUCCINATE 剂型/给药途径:INJECTABLE;SUBCUTANEOUS 规格:EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
020080 003 NDA IMITREX STATDOSE SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Prescription Yes Yes AB 1996/12/23 GLAXOSMITHKLINE
090358 001 ANDA SUMATRIPTAN SUCCINATE SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Discontinued No No AB 2011/06/21 SUN PHARM
090495 001 ANDA SUMATRIPTAN SUCCINATE SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Prescription No No AB 2014/01/29 DR REDDYS
078319 002 ANDA SUMATRIPTAN SUCCINATE SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Discontinued No No AB 2015/12/10 ANTARES PHARMA INC
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database